Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Isabel Gallegos Sancho"'
Autor:
Jose Luis Alonso, Alicia de Luna, Manuel Ruiz Borrego, Eva Ciruelos, Maria Isabel Gallegos Sancho, Santiago González-Santiago, Jose Ignacio Chacon, Marta Santisteban Eslava, Sonia Servitja, Pilar de la Morena, Elsa Dalmau, Cristina Saura
Publikováno v:
Breast cancer research and treatment. 184(2)
Neoadjuvant clinical trials with dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy demonstrated high rates of pathological complete response (pCR) in HER2-positive early breast cancer (BC). We investigated whether the benefit on pC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a985bb4a1d233d1b61133f6d826b7c6f
https://pubmed.ncbi.nlm.nih.gov/32876911
https://pubmed.ncbi.nlm.nih.gov/32876911
Publikováno v:
Future oncology (London, England). 14(7s)
Triple-negative breast cancers are defined as tumors negative for estrogen receptors, progesterone receptors and human EGFR2. These tumors exhibit diverse biological behavior and have a poor prognosis; chemotherapy is the mainstay of treatment. The f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c953d188869730ccce84d5132dba723
https://pubmed.ncbi.nlm.nih.gov/29611754
https://pubmed.ncbi.nlm.nih.gov/29611754
Autor:
R. García Campelo, L. Calvo Martínez, B. Sanromán Budiño, M. Quindós Varela, G. Alonso Curbera, S. Antolín Novoa, M.S. López Facal, M. Isabel Gallegos Sancho, M. Valladares Ayerbes, L. M. Antón Aparicio, M. Reboredo López
Publikováno v:
Clinical breast cancer. 7(1)
We report the case of a patient with subacute cerebellar degeneration presenting as paraneoplastic syndrome, preceding the final diagnosis of breast cancer. The tumor had high HER2 overexpression, so a weekly regimen of paclitaxel/trastuzumab was sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0ea70b3bacfe408f00e205b522fee77
https://pubmed.ncbi.nlm.nih.gov/16764747
https://pubmed.ncbi.nlm.nih.gov/16764747
Autor:
Isabel Gallegos Sancho, Maria Dolores Torregrosa, Javier Cassinello, Andrés García-Palomo, Cristina Llorca, M. Mendez, Ramon Perez-Carrion, Gustavo Catalan, Esperanza J. Carcache de Blanco, Rosa Llorente, Antonia Perelló, Maria Jose Garcia Lopez, Coralia Bueno, Antonio J. Fernández, Xabier Mielgo Rubio, Elena Galve Calvo, Luis Manso, Jose Ignacio Chacon, Hernán Cortés-Funes, Inaki Alvarez
Publikováno v:
Web of Science
e12020 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites, location of metastases and patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53b99ac310f7bef761d692841f6c02f5
https://doi.org/10.1200/jco.2013.31.15_suppl.e12020
https://doi.org/10.1200/jco.2013.31.15_suppl.e12020
Autor:
Javier Cassinello, Maria Jose Garcia Lopez, Santos Enrech, Blanca Hernando, Maria Dolores Torregrosa, Elena Galve Calvo, Esperanza J. Carcache de Blanco, Isabel Gallegos Sancho, Gustavo Catalan, Andres Garcia Palomo, Cristina Llorca, Hernán Cortés-Funes, Ramon Perez-Carrion, Inaki Alvarez, Xabier Mielgo Rubio, Rosa Llorente, Mauro Oruezabal, Luis Manso, Miguel Angel Lara, Jose Ignacio Chacon Lopez-Muniz
Publikováno v:
Journal of Clinical Oncology. 30:e11074-e11074
e11074 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites and location of metastases and patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a88b2074c4e896ddaf45b694dc0c164d
https://doi.org/10.1200/jco.2012.30.15_suppl.e11074
https://doi.org/10.1200/jco.2012.30.15_suppl.e11074